Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24716892 | 0.69 | ERCC5 (0.34) | — | |
| SCHEMBL1992010 | 0.63 | LMNA (0.30) | — | |
| Ethane SCHEMBL16588819 | 0.61 | — | — | |
| SCHEMBL31321330 | 0.60 | ADRB2 (0.31) | — | |
| SCHEMBL9595093 | 0.60 | PDPK1 (0.46) | PDPK1SMN1; SMN2 | |
| SCHEMBL24323491 | 0.59 | PDPK1 (0.31) | PDPK1 | |
| SCHEMBL12565907 | 0.59 | PARP14 (0.34) | — | |
| SCHEMBL12605413 | 0.59 | HTR2A (0.45) | — | |
| SCHEMBL25030573 | 0.58 | — | — | |
| SCHEMBL18853889 | 0.58 | GPR84 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345905-B2 | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | BETA PHARMA CANADA INC. (CA) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | HDAC6, HDAC1, HDAC7 | PDPK1 1739/4885SMN1; SMN2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.